Based on the information discussed in preceding sections, we concluded that inhibition of TG2 could be a promising therapeutic target for reversing intrinsic resistance of pancreatic cancer cells to chemotherapeutic drugs. This evidence concerns the gene TGM2 and familial pancreatic carcinoma.